GlassScriptPhysician profile
Keela K Weeks
NPI 1831315431
$2,756.23
in general payments reported to CMS, 2019-2025
19 companies · $797 in 2025
The $797 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.48 · 2022: $398 · 2023: $566 · 2024: $981 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.12 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.11 | 2022-2025 | |
| Lilly USA, LLC | $508.46 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $290.48 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astellas Pharma US INC | $243.69 | 2023-2025 | Veozah |
| Pfizer INC. | $115.06 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $67.38 | 2024-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $64.02 | 2021-2023 | Shingrix, Arexvy |
| Exact Sciences Corporation | $56.39 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $46.11 | 2022-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $41.19 | 2022-2023 | Livalo, Seglentis |
| Lundbeck LLC | $26.49 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $25.61 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $25.27 | 2025 | Nuzyra |
| Abbott Laboratories | $21.71 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.41 | 2025 | |
| Supernus Pharmaceuticals, INC. | $21.41 | 2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $18.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keela Weeks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.